Compare CAAP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAP | TVTX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.3B |
| IPO Year | 2017 | 2013 |
| Metric | CAAP | TVTX |
|---|---|---|
| Price | $25.11 | $57.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $26.73 | ★ $40.62 |
| AVG Volume (30 Days) | 185.9K | ★ 1.4M |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | $44.76 |
| Revenue Next Year | $2.36 | $35.51 |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.36 | $15.03 |
| 52 Week High | $30.50 | $60.10 |
| Indicator | CAAP | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 57.47 |
| Support Level | $24.78 | $53.93 |
| Resistance Level | $26.76 | $59.89 |
| Average True Range (ATR) | 0.66 | 2.58 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 61.62 | 55.36 |
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.